Citigroup
KROS icon

Citigroup’s Keros Therapeutics KROS Stock Holding History

Citigroup’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,100
Closed -$819K – 5898
2024
Q3 		$819K Buy
+14,100
New +$696K ﹤0.01% 3415

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Citigroup's KROS Position: Q2 2026 in Review

Citigroup increased its Keros Therapeutics (KROS) stake by 308% in Q2 2026, buying an estimated $75.8K and bringing the position to 9,015 shares worth $96.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4711.

Citigroup first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $19.8M in Q4 2022. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Citigroup held 9,015 shares of Keros Therapeutics worth $96.5K as of Q2 2026.
  • Citigroup bought 6,807 Keros Therapeutics shares in Q2 2026, an estimated $75.8K.
  • Keros Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4711 holding.
  • Citigroup first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Citigroup's Keros Therapeutics position peaked at $19.8M in Q4 2022.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.